Brett Sharp

Brett Sharp

Auto-generated profile, based on publicly available information

Brett Sharp

University of British Columbia, Canada

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 September 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
FFFanan Fattah
Fanan Fattah
RLRichard Lester
Richard Lester
KKKhumbo Kalua
Khumbo Kalua
BSBrett Sharp
Brett Sharp
AHAdam Houston
Adam Houston
Kishor M WasanKishor M Wasan
Kishor M Wasan
The COVID-19 pandemic revealed stark inequities in access to life-saving technologies and innovations, particularly for countries in the Global South. While scientific advances were rapid, the benefits of those breakthroughs were not equitably shared, highlighting deep structural imbalances in global health governance. In response, Canadian institutions must lead by example to ensure that future innovations arising from publicly funded research are made equitably accessible. The Global Health Access and Equity Workshop, held in March 2025 by the Neglected Global Diseases Initiative at UBC, convened experts from academia, civil society, and government to identify key barriers and propose a framework for action. This viewpoint outlines the workshop’s vision, summarizes outcomes, and calls for the establishment of a Canadian framework guided by Global Access and Equity Principles (GAEP) to promote health equity globally and fulfill Canada’s moral, scientific, and policy obligations in the post-pandemic era.

25 November 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
FFFanan Fattah
Fanan Fattah
RLRichard Lester
Richard Lester
KKKhumbo Kalua
Khumbo Kalua
BSBrett Sharp
Brett Sharp
Kishor M WasanKishor M Wasan
Kishor M Wasan
In July 2023, the World Health Organization (WHO) released the 23rd Model List of Essential Medicines (EML) for adults and the 9th Model List of EML for children. These lists serve as global references for essential medicines that should be universally available, accessible and affordable. This editorial explores recent updates to the WHO EML lists, with a particular focus on medicines addressing neglected tropical diseases (NTDs). We discuss the persistent barriers to equitable access, including economic, regulatory, and logistical challenges; highlight global initiatives aimed at improving accessibility; and propose strategies to bridge the gap in essential medicine access. We emphasize the need for international collaboration, increased funding for research institutions, pharmaceutical companies, and global health initiatives to support the development of novel treatments for NTDs, and innovative distribution approaches to ensure these medications reach underserved populations.